share_log

加科思-B(01167.HK)在2024年第66届美国血液学年会上展示了BET抑制剂JAB-8263治疗骨髓纤维化的初步临床数据

JACOS-B (01167.HK) presented initial clinical data on the BET inhibitor JAB-8263 for the treatment of myelofibrosis at the 66th annual conference of hematology in 2024 in the usa.

Gelonghui Finance ·  Dec 9, 2024 07:52

On December 9, Gelonghui reported that JAK-8263 (01167.HK) announced that the company presented preliminary data from a Phase I clinical trial of the BET inhibitor JAB-8263 for the treatment of myelofibrosis (MF) at the 66th American Society of Hematology (ASH) annual meeting held in San Diego, California.

Data shows that JAB-8263 has good tolerability, with a recommended Phase II dose of 0.3 mg (administered daily). The preliminary efficacy data for JAB-8263 as a monotherapy for myelofibrosis is encouraging, with most patients experiencing a reduction in spleen volume and a decrease in the total symptom score (TSS).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment